Education
About Us
Working with TipRanks
Follow Us
Bayer (BAYRY)
OTHER OTC:BAYRY
Top Page
Bayer
(OTC:BAYRY)
62Neutral
Bayer (BAYRY) vs. S&P 500 (SPY)
Market Cap
$23.92B
Dividend Yield0.37%
Average Volume (3M)24.77K
Price to Earnings (P/E)―
Beta (1Y)0.53
Revenue Growth-2.07%
EPS Growth13.27%
CountryUS
Employees90,587
SectorHealthcare
Sector Strength78
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-0.72
Shares Outstanding3,929,696,000
10 Day Avg. Volume0
30 Day Avg. Volume24,768
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.16
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.20Price Target Upside21.83% Upside
Rating ConsensusHold
Number of Analyst Covering1
Bayer Business Overview & Revenue Model
Company DescriptionBayer AG is a global life sciences company headquartered in Leverkusen, Germany, with core competencies in the areas of health care and agriculture. The company's operations are divided into three main sectors: Pharmaceuticals, Consumer Health, and Crop Science. Bayer is renowned for its innovative products and solutions in areas such as prescription medicines, over-the-counter health products, seeds, and crop protection products.
How the Company Makes MoneyBayer makes money through its diversified portfolio of products and services in the pharmaceuticals, consumer health, and crop science sectors. The Pharmaceuticals division generates revenue primarily from the sale of prescription drugs that treat cardiovascular diseases, oncology, women's health, and other medical conditions. The Consumer Health division earns money through the sale of non-prescription products, including vitamins, dietary supplements, dermatological products, and analgesics. The Crop Science division contributes to Bayer's revenue by providing seeds, crop protection products, and digital farming solutions to farmers worldwide. Additionally, significant partnerships with research institutions, technology companies, and other industry players enhance Bayer's innovation capabilities and market reach, further supporting its revenue streams.
Bayer Financial Statement Overview
Summary
Bayer's financial health presents a mixed picture. While the company struggles with declining revenue and profitability, its cash flow generation remains robust. High debt levels pose a risk, but the company's substantial asset base offers some stability. Continued focus on cash management and operational improvements will be crucial for future performance.Income Statement
Bayer has faced declining revenue and profitability with a notable net loss in recent years. Revenue decreased by 2.2% from 2023 to 2024, and the net profit margin is negative due to losses. The company has not generated EBIT in the latest period, indicating operational challenges. However, the EBITDA margin remains positive, suggesting some operational efficiency.55
Neutral
Balance Sheet
The balance sheet shows a significant level of debt, with a debt-to-equity ratio of 1.28 in 2024, indicating high leverage. The equity ratio is 28.8%, showing a moderate reliance on equity financing. Return on equity is negative due to net losses, posing a risk to shareholders. However, the company's asset base remains strong, providing stability.60
Neutral
Cash Flow
Bayer's cash flow is relatively strong, with a positive free cash flow growth of 93.9% from 2023 to 2024, driven by increased operating cash flow. The operating cash flow to net income ratio is high, indicating good cash conversion, despite overall losses. Free cash flow to net income is also positive, showing cash generation capability despite profitability challenges.70
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 46.61B | 47.64B | 50.74B | 44.08B | 41.40B | Gross Profit |
| 25.34B | 27.89B | 30.87B | 27.27B | 22.26B | EBIT |
| 0.00 | -150.00M | 6.26B | 6.97B | -2.94B | EBITDA |
| 8.81B | 10.45B | 13.03B | 6.45B | 10.32B | Net Income Common Stockholders |
| -2.55B | -2.94B | 4.15B | 1.00B | -15.56B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 8.09B | 10.59B | 10.15B | 7.74B | 11.88B | Total Assets |
| 110.85B | 116.26B | 124.88B | 120.24B | 117.05B | Total Debt |
| 40.70B | 42.87B | 41.32B | 39.53B | 41.55B | Net Debt |
| 34.51B | 36.97B | 36.15B | 34.97B | 37.36B | Total Liabilities |
| 78.81B | 83.18B | 85.95B | 87.07B | 86.35B | Stockholders Equity |
| 31.91B | 32.93B | 38.77B | 33.02B | 30.52B |
| Cash Flow | Free Cash Flow | |||
| 4.59B | 2.37B | 4.14B | 2.48B | 2.48B | Operating Cash Flow |
| 7.37B | 5.12B | 7.09B | 5.09B | 4.90B | Investing Cash Flow |
| 164.00M | -3.52B | -2.38B | 855.00M | -4.07B | Financing Cash Flow |
| -7.18B | -679.00M | -4.22B | -5.64B | 423.00M |
Bayer Technical Analysis
Negative
5.91
Price Trends
5.95
Negative
5.60
Positive
6.50
Negative
Market Momentum
0.03
Positive
46.62
Neutral
7.19
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BAYRY, the sentiment is Negative. The current price of 5.91 is below the 20-day moving average (MA) of 6.27, below the 50-day MA of 5.95, and below the 200-day MA of 6.50, indicating a bearish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 46.62 is Neutral, neither overbought nor oversold. The STOCH value of 7.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BAYRY.
Bayer Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $218.22B | 12.82 | 40.81% | 3.66% | 6.85% | 4577.79% | |
69 Neutral | $748.05B | 67.36 | 84.84% | 0.68% | 32.00% | 102.18% | |
69 Neutral | $385.14B | 27.60 | 20.06% | 3.10% | -4.51% | 3.69% | |
68 Neutral | $137.76B | 17.24 | 9.05% | 6.96% | 8.77% | 272.80% | |
62 Neutral | $23.92B | ― | -8.12% | 0.37% | -2.07% | 13.27% | |
60 Neutral | $117.65B | ― | -39.10% | 4.18% | 7.32% | -214.24% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% |
* Healthcare Sector Average
Performance Comparison
BAYRY
Bayer
5.52
-1.88
-25.41%
BMY
Bristol-Myers Squibb
55.30
6.38
13.04%
LLY
Eli Lilly & Co
738.21
-40.94
-5.25%
JNJ
Johnson & Johnson
153.24
5.59
3.79%
MRK
Merck & Company
86.39
-37.91
-30.50%
PFE
Pfizer
24.29
-0.80
-3.19%
Bayer Earnings Call Summary
Earnings Call Date: Mar 5, 2025 | % Change Since: -4.52% | Next Earnings Date: May 13, 2025
Earnings Call Sentiment Neutral
The earnings call reflected a mixed sentiment with strong performance in Pharmaceuticals and Consumer Health segments, driven by strategic innovation and operational efficiency. However, this was offset by significant challenges in the Crop Science division and ongoing regulatory and litigation issues, leading to a cautious outlook for 2025.Highlights
Pharmaceuticals Success
Pharmaceuticals sales are up, with expectations to deliver at the upper end of upgraded guidance in both sales and earnings. Nubeqa reached blockbuster status with a growth of 83% and Kerendia sales nearly doubled.
Consumer Health Growth
Consumer Health achieved a 6% year-over-year sales growth, reaching EUR 1.4 billion, with a clean EBITDA margin improvement to 25.5%, a 330 basis point increase year-over-year.
Dynamic Shared Ownership Model
The new operating model has led to a reduction of 5,500 jobs, primarily managerial, improving operational efficiency and cash flow.
Innovative Agricultural Products
Launch of Precion Smart Corn in multiple countries, with plans for a biotech version in 2027. Farmers have reported significant yield improvements and resistance to environmental challenges.
Strategic Focus on Innovation
10 blockbusters planned for launch over the next 10 years, including new insecticides and herbicides to enhance competitive differentiation.
Lowlights
Crop Science Underperformance
Crop Science is expected to come in under guidance for 2024 due to weather challenges, disease pressure, and generic pricing pressures, leading to a reduced 2024 target.
Regulatory and Pricing Challenges
Significant regulatory pressures in Crop Protection and pricing challenges in the generic market are impacting margins and future outlook.
Litigation and Impairment Concerns
Ongoing litigation issues with glyphosate and PCBs, with a EUR 3.8 billion impairment in Crop Science driven by reduced business prospects and regulatory uncertainties.
Foreign Exchange Headwinds
Nearly EUR 440 million FX headwind to the top line in Q3, impacting divisional margins and core earnings per share.
Xarelto Generic Pressure
Xarelto sales declined by 23% in Q3 due to accelerating generic headwinds, impacting profitability despite ongoing efforts to defend IP rights.
Company Guidance
In the Q3 2024 earnings call for BAYN.DE, the company provided detailed guidance and insights into their performance metrics. They expect to meet full-year targets for sales growth, core earnings per share, and free cash flow, despite a forecasted 2% decline in the agriculture market. Pharmaceuticals is performing well, with sales projected at the upper end of upgraded guidance owing to the success of products like Nubeqa and Kerendia. Consumer Health is growing, though not as rapidly as anticipated due to market slowdowns in the U.S. and China, and Crop Science is facing challenges from regulatory and pricing pressures. Clean EBITDA is expected to be lower, but the company is focused on optimizing P&L, managing costs, and strengthening innovation pipelines, particularly with upcoming launches like Precision Smart Corn in 2027. For 2025, they anticipate a cautious market environment with potential regulatory impacts, but remain committed to operational efficiency and strategic innovation to drive future growth.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.